Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Accuray reports strong Q1 2023 earnings and focuses on global expansion

Accuray's Q1 2023 earnings call highlighted strong financial performance, with significant revenue growth and increased system orders. The company is focused on driving profitability expansion and expanding patient access to its technologies worldwide. While facing challenges in managing backlog and addressing performance in China, Accuray is actively pursuing opportunities for margin expansion and business growth.

Accuray delivers record Q2 performance, eyes growth opportunities ahead

Accuray's Q2 2023 performance highlighted record system deliveries and strong order growth, with a focus on radiation oncology services.
Despite challenges in revenue decline and backlog, strategic wins and progress in key regions position the company for future growth.
Opportunities lie in market expansion in the Americas, strategic wins in key regions, and advancements in China.
Maintaining growth momentum, addressing revenue challenges, and capitalizing on opportunities are key focus areas for Accuray.

Accuray reports strong Q3 earnings, eyes global expansion and partnerships

Accuray's Q3 2023 earnings call showcased robust financial performance, strategic initiatives to drive profitability, and a commitment to global expansion. Despite challenges in product positioning and market competition, the company's focus on innovation and partnerships positions it well for future growth and market leadership.

Accuray reports 8% revenue growth, eyes margin expansion and growth

Accuray's Q4 2023 performance showed revenue growth, strong demand for Radixact, and strategic order wins. While facing challenges in product margins and supply chain, the company aims for margin expansion and growth opportunities in the second half of FY '24. Implementation of a new ERP system is expected to drive operational efficiencies and profitability insights.

Accuray reports strong Q1 earnings, eyes growth in China and India

Accuray delivered a robust Q1 performance with revenue and EBITDA growth, backed by strategic wins in key markets like China and India. The company's focus on new product innovations and cost optimization efforts contributed to its positive results. While challenges related to inflation exist, Accuray remains optimistic about reimbursement changes and market opportunities.

Accuray reports strong Q2 performance with growth opportunities ahead

Accuray's Q2 2024 showcased robust order growth, service revenue increase, and global demand strength. The company is focused on margin expansion and new product market clearances for future growth.

Accuray faces challenges in Q3 2024 but remains optimistic

Accuray's Q3 2024 performance was impacted by challenges but showed resilience with global order growth and strategic focus on long-term goals. Despite revised guidance, the company remains optimistic about future growth drivers and is prepared for gradual recovery post-COVID.

Accuray reports robust Q1 performance and raises FY '25 guidance

Accuray's Q1 2025 performance reflects strong revenue growth, margin expansion efforts, and positive market reception for its innovative products and services.
While facing challenges in certain markets and regulatory timelines, the company remains optimistic about future revenue trends and growth opportunities globally.
By raising its revenue guidance and focusing on operational efficiency, Accuray aims to capitalize on market opportunities and navigate potential challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?

Accuray (ARAY) Up 1.6% Since Last Earnings Report: Can It Continue?

Company to Take Part in Fireside Chat Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST MADISON, Wis. , Feb. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024.

Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

B2Gold

ChargePoint Holdings

Cipher Mining

VAALCO Energy

Wag! Group Co

Planet Labs

While most financial advisors will probably steer you away from under $5 stocks, they have their benefits. Just like in football – the American kind – you can't just run up the gut.

7 Screaming Stock Buys for Under $5

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is a center of excellence and recognized leader in the treatment of cancer in the province of Quebec The Radixact System is equipped with ClearRT™ and Synchrony®, advanced technologies designed to improve treatment outcomes for more patients each day MADISON, Wis. , Feb. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec's Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is the first in Canada to treat cancer patients using the company's Radixact ® radiation therapy delivery system.

Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System

MADISON, Wis. , Feb. 5, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place on February 13, 2024.

Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.

Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts

Accuray Incorporated (ARAY) Q2 2024 Earnings Call Transcript

The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Accuray (ARAY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

19% Order Growth YOY; 8% Service Revenue Expansion; Confirms FY24 Guidance MADISON, Wis. , Jan. 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter and six-months ended December 31, 2023.

Accuray Reports Fiscal 2024 Second Quarter Financial Results

Besides Wall Street's top -and-bottom-line estimates for Accuray (ARAY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Unveiling Accuray (ARAY) Q2 Outlook: Wall Street Estimates for Key Metrics

Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.

Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment

New System Will Play a Key Role in Delivering Radiation Treatments in One of the Largest Cancer Facilities in Washington State MADISON, Wis. , Jan. 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife® S7™ System, the hospital's second CyberKnife radiation delivery device purchase.

Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray CyberKnife® System, a Robotic Delivery Device That Makes Extremely Precise Radiation Treatments Possible in 1-5 Sessions

MADISON, Wis. , Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m.

Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024

Accuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff.

Accuray (ARAY) Launches VitalHold in Japan for Use With Radixact

MADISON, Wis. , Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan beginning November 30, 2023.

Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System

Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.

Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top

Accuray Incorporated (NASDAQ:ARAY ) Q1 2024 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jesse Chew - SVP and Chief Legal Officer Suzanne Winter - President and CEO Ali Pervaiz - CFO Conference Call Participants Young Li - Jefferies Brooks O'Neil - Lake Street Capital Markets Brandon Carney - B. Riley Operator Good afternoon and welcome to the Accuray's First Quarter 2024 Conference Call.

Accuray Incorporated (ARAY) Q1 2024 Earnings Call Transcript

The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Accuray (ARAY) Q1 Earnings: A Look at Key Metrics

Company Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance MADISON, Wis. , Nov. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2024 ended September 30, 2023.

Accuray Reports Fiscal 2024 First Quarter Financial Results

MADISON, Wis. , Oct. 31, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the 14th Annual Jefferies London Healthcare Conference.

Accuray to Participate in the 14th Annual Jefferies London Healthcare Conference

MADISON, Wis. , Oct. 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2024, ended September 30, 2023, during a conference call hosted by company management at 1:30 p.m.

Accuray to Report First Quarter Fiscal 2024 Financial Results on November 7, 2023

Accuray's China JV recently received approval to sell its locally-produced Tomo C rad-onc system for China's Type B market - an opportunity that management estimates at $3B over 5 years. Management has a good track record in China, but there's a long history here of not delivering on potential growth opportunities and both Varian and Elekta are targeting China. China isn't the only driver, as Japan and segments of the U.S. market (including SBRT) could perform better, but execution is paramount.

With Chinese Type B Approval In Hand, 'Now Or Never' Approaches For Accuray

Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.

Accuray's (ARAY) Tomo C Radiation System Gets Approval in China

MADISON, Wis. , Oct. 3, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration (NMPA).

News for Accuray Stock (ARAY)